Get the Stockscreener App
1.49
7.19%
0.10
After Hours:
1.49
Vivani Medical Inc stock is traded at $1.49, with a volume of 479.08K.
It is up +7.19% in the last 24 hours and up +6.43% over the past month.
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.
See More
Previous Close:
$1.39
Open:
$1.4
24h Volume:
479.08K
Relative Volume:
1.08
Market Cap:
$134.40M
Revenue:
-
Net Income/Loss:
$-27.09M
P/E Ratio:
-3.6918
EPS:
-0.4036
Net Cash Flow:
$-26.52M
1W Performance:
+4.93%
1M Performance:
+6.43%
6M Performance:
+26.27%
1Y Performance:
+8.76%
1-Day Range:
$1.38
$1.515
1-Week Range:
$1.35
$1.515
52-Week Range:
$0.9228
$1.92
Vivani Medical Inc Stock (VANI) Company Profile
Name
Vivani Medical Inc
Sector
Industry
Phone
415-506-8462
Address
1350 S. LOOP ROAD, ALAMEDA
Compare VANI vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VANI
Vivani Medical Inc
|
1.49 | 127.19M | 0 | -27.09M | -26.52M | -0.4036 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vivani Medical Inc Stock (VANI) Latest News
Vivani Medical to Participate in Upcoming Lake Street and H.C. Wainwright Investor Conferences - Quiver Quantitative
Two New York conferences are planned for Vivani Medical - Stock Titan
Vivani Medical Announces Participation in Upcoming Investor Conferences - globenewswire.com
VANI Stock Price, Quote & Chart - ChartMill
Vivani (VANI) Quarter in Review: EPS Lands Above Forecast in the Latest Session; Trading Response - Vinanet
Maxim Group Maintains Vivani Medical(VANI.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Form 8K Vivani Medical Inc For: 17 August By Investing.com - Investing.com Nigeria
Vivani Medical posts slide presentation under Reg FD; Exhibit 99.1 attached - TradingView
Vivani Medical posts investor deck outlining NanoPortal ultra-long-acting GLP-1 implant strategy for obesity market - Bitget
Wall Street Zen Upgrades Vivani Medical (NASDAQ:VANI) to "Hold" - MarketBeat
Vivani Medical (NASDAQ: VANI) Completes Full Enrollment In Semaglutide Implant Trial, Strikes Novo Nordisk Deal - foreignpolicyjournal.com
VANI Q1 2026 Earnings: Narrower Loss Slightly Beats Consensus, Shares Rise 4.48%Balance Sheet Strength - vinanet.vn
Vivani Medical Fully Enrolls Phase 1 Semaglutide Implant Trial; Data Due November - Minichart
Form 8K Vivani Medical Inc For: 13 August By Investing.com - Investing.com Nigeria
Vivani Medical (NASDAQ:VANI) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Vivani Medical Q2 losses narrow 41% YoY; signs Novo Nordisk deal - scanx.trade
Vivani Medical: Q2 Earnings Snapshot - Barchart.com
Vivani Medical Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
Vivani Medical (VANI) widens GLP‑1 pipeline, funds runway into Q2 2027 - Stock Titan
ClearOne (CLRO) details Cortigent reverse merger, 78% Vivani control and new equity plan - Stock Titan
ClearOne to merge with Cortigent, pivoting to neurotech under new Nasdaq ticker - Dealroom
Vivani Medical Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
ClearOne Inc. (CLRO) majority holder cancels warrant as Cortigent merger proceeds - Stock Titan
Form 8K Vivani Medical Inc For: 6 August By Investing.com - Investing.com Nigeria
Vivani Medical Completes Enrollment, Dosing in Phase 1 SLIM-1 Trial - marketscreener.com
Vivani Completes Enrollment in SLIM-1 Semaglutide Implant Trial - TipRanks
Form 8K Vivani Medical Inc For: 6 August - Investing.com India
Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management - The Manila Times
Semaglutide implant trial doses all 20 participants; data expected in November - Stock Titan
Vivani Medical completes dosing in Phase 1 tria... - pluang.com
ClearOne Cancels 437,500 First Finance Warrants at $5.00 Amid Cortigent Merger Process - TradingView
Vivani Medical (VANI) to Announce Earnings on Wednesday - MarketBeat
Vivani Medical (VANI) Dips 1.54% to $1.28, Holding Within Key $1.22 Support and $1.34 Resistance RangePassive Flow - vinanet.vn
Enterprise value to EBITDA forward of Vivani Medical, Inc. – NASDAQ:VANI - TradingView
Vivani Medical, Inc. Revenue Breakdown – NASDAQ:VANI - TradingView
Form 4 Vivani Medical Inc For: 30 July By Investing.com - Investing.com Nigeria
Vivani Medical (VANI) awards CEO 200K stock options and 100K RSUs - Stock Titan
Vivani Medical (NASDAQ: VANI) grants COO options and performance RSUs - Stock Titan
Vivani Medical (NASDAQ: VANI) awards CFO 75,000 options and RSUs - Stock Titan
Form 4 Vivani Medical Inc For: 28 July - Investing.com India
Form 4 Vivani Medical Inc For: 28 July By Investing.com - Investing.com Canada
Vivani Medical, Inc. (VANI) awards stock options in lieu of director fees - Stock Titan
Vivani Medical (VANI) Slides Nearly 8% as Shares Approach Key SupportPrice Momentum Stocks - dars.gov.et
Vivani Medical Market Sentiment - Benzinga España
Vivani Medical Inc. Revenue Breakdown – FWB:U5P - TradingView
Vivani Medical Inc (VANI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management - Bernama
Vivani Medical Inc (VANI) Cash Flow - TradingKey
Vivani Medical Inc (VANI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vivani Medical Inc (VANI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vivani Medical Inc Stock (VANI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vivani Medical Inc Stock (VANI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Williams Gregg | Director |
Jun 15 '26 |
Buy |
1.26 |
1,587,301 |
1,999,999 |
36,119,086 |
| Williams Gregg | Director |
May 15 '26 |
Buy |
1.26 |
1,587,301 |
1,999,999 |
34,531,785 |
| Williams Gregg | Director |
Apr 15 '26 |
Buy |
1.26 |
1,587,301 |
1,999,999 |
32,944,484 |
| Williams Gregg | Director |
Mar 15 '26 |
Buy |
1.07 |
1,575,231 |
1,683,335 |
31,357,183 |
| Williams Gregg | Director |
Feb 15 '26 |
Buy |
1.06 |
1,866,492 |
1,983,333 |
29,781,952 |
| Williams Gregg | Director |
Jan 27 '26 |
Buy |
1.48 |
1,351,351 |
1,999,999 |
27,915,460 |
| Williams Gregg | Director |
Jan 15 '26 |
Buy |
1.14 |
1,737,765 |
1,983,334 |
26,564,109 |
| Mendelsohn Aaron | Director |
Dec 29 '25 |
Buy |
1.23 |
20,000 |
24,600 |
188,170 |
| Williams Gregg | Director |
Dec 15 '25 |
Buy |
1.14 |
1,737,765 |
1,983,334 |
24,826,344 |
| Williams Gregg | Director |
Nov 15 '25 |
Buy |
1.14 |
1,737,764 |
1,983,333 |
23,088,579 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):